Ocular toxicities in chimeric antigen receptor T-cell therapy : a real-world study leveraging FAERS database
Aim: The purpose of this study was to comprehensively explore the ocular toxicity associated with chimeric antigen receptor (CAR) T-cell therapy. Materials & methods: Data were assembled from the US FDA's Adverse Event Reporting System (FAERS) database from 2017 to 2023. Information component and reporting odds ratio methods were used for signal detection in total/categorized CAR T-cell therapy. Results: A total of 17 positive signals (preferred term) were detected, yet none of them were documented in the product information. Some adverse events were with death outcomes and overlapped a lot with cytokine-release syndrome. Conclusion: The ocular adverse events associated with CAR-T cell therapy are noteworthy, and it is imperative to maintain increased alertness and institute early intervention strategies.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:16 |
|---|---|
| Enthalten in: |
Immunotherapy - 16(2024), 3 vom: 02. Jan., Seite 161-172 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Zhao, Na [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Chimeric antigen receptor T cell |
|---|
| Anmerkungen: |
Date Completed 05.01.2024 Date Revised 05.01.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.2217/imt-2023-0220 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM366168010 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM366168010 | ||
| 003 | DE-627 | ||
| 005 | 20240108142215.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231227s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2217/imt-2023-0220 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1249.xml |
| 035 | |a (DE-627)NLM366168010 | ||
| 035 | |a (NLM)38126138 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Zhao, Na |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Ocular toxicities in chimeric antigen receptor T-cell therapy |b a real-world study leveraging FAERS database |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 05.01.2024 | ||
| 500 | |a Date Revised 05.01.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Aim: The purpose of this study was to comprehensively explore the ocular toxicity associated with chimeric antigen receptor (CAR) T-cell therapy. Materials & methods: Data were assembled from the US FDA's Adverse Event Reporting System (FAERS) database from 2017 to 2023. Information component and reporting odds ratio methods were used for signal detection in total/categorized CAR T-cell therapy. Results: A total of 17 positive signals (preferred term) were detected, yet none of them were documented in the product information. Some adverse events were with death outcomes and overlapped a lot with cytokine-release syndrome. Conclusion: The ocular adverse events associated with CAR-T cell therapy are noteworthy, and it is imperative to maintain increased alertness and institute early intervention strategies | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a FAERS database | |
| 650 | 4 | |a chimeric antigen receptor T cell | |
| 650 | 4 | |a disproportionality analysis | |
| 650 | 4 | |a information component | |
| 650 | 4 | |a ocular toxicity | |
| 650 | 4 | |a reporting odds ratio | |
| 650 | 7 | |a Receptors, Chimeric Antigen |2 NLM | |
| 700 | 1 | |a Hu, Fangyuan |e verfasserin |4 aut | |
| 700 | 1 | |a Zhai, Yinghong |e verfasserin |4 aut | |
| 700 | 1 | |a Ye, Xia |e verfasserin |4 aut | |
| 700 | 1 | |a Ruan, Yiming |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Zhen |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Zhiyan |e verfasserin |4 aut | |
| 700 | 1 | |a Shen, Wei |e verfasserin |4 aut | |
| 700 | 1 | |a Yuan, Lei |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Immunotherapy |d 2009 |g 16(2024), 3 vom: 02. Jan., Seite 161-172 |w (DE-627)NLM19257163X |x 1750-7448 |7 nnns |
| 773 | 1 | 8 | |g volume:16 |g year:2024 |g number:3 |g day:02 |g month:01 |g pages:161-172 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2217/imt-2023-0220 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 16 |j 2024 |e 3 |b 02 |c 01 |h 161-172 | ||